Preview

Пульмонология

Расширенный поиск

Эффективность и безопасность гемифлоксацина при инфекционном обострении хронической обструктивной болезни легких: открытое проспективное мультицентровое исследование

https://doi.org/10.18093/0869-0189-2008-0-6-39-47

Полный текст:

Аннотация

Изучали клиническую, бактериологическую эффективность и переносимость гемифлоксацина при лечении больных с обострением хронической обструктивной болезни легких (ХОБЛ), госпитализированных в пульмонологические отделения стационаров. Дизайн исследования: открытое, несравнительное, проспективное. В нем участвовали 25 пульмонологических центров России, исследуемую группу составили 222 пациента с обострением ХОБЛ (156 мужчин и 66 женщин, средний возраст – 56,4 ± 11,9 года). 70,3 % из них были отнесены к I типу обострения по Anthonisen. Пациентам назначали антибактериальный препарат гемифлоксацин (Фактив® , "Верофарм", Россия) по 1 капсуле (320 мг) внутрь в течение 7 дней. Оценка клинической, микробиологической эффективности и переносимости терапии проводилась через 7–8 и 14–16 дней от начала лечения. К 7–8-му дням исследования отмечались статистически значимое уменьшение кашля, одышки, снижение объема и степени "гнойности" мокроты. Основные исходы лечения больных ХОБЛ: без изменений состояние осталось у 3,6 %, т. е. клиническая эффективность терапии гемифлоксацином составила 94,4 %. Посев мокроты был выполнен у 73,0 % больных, и у 60,4 % пациентов были выделены патогенные микроорганизмы. Ведущими возбудителями были Streptococcus pneumoniae (37,7 %) и Haemophilus influenzae (27,8 %). Эрадикация и предполагаемая эрадикация микроорганизмов были достигнуты у 69,4 и 26,9 % больных соответственно. Бактериологическая эффективность терапии гемифлоксацином составила 96,3 %. Побочные явления были у 15 пациентов, наиболее часто – диарея (4,7 %). Все побочные реакции были легкими и транзиторными и не требовали отмены препарата. В исследовании показана высокая эффективность антибактериального препарата гемифлоксацина в терапии госпитализированных больных с обострением ХОБЛ. Он хорошо переносится больными и удобен для приема.

Об авторах

С. Н. Авдеев
ФГУ НИИ пульмонологии ФМБА России
Россия
Екатеринбург


Г. Е. Баймаканова
ФГУ НИИ пульмонологии ФМБА России
Россия
Екатеринбург


Е. Н. Гайдар
Отделение пульмонологии клинической больницы г. Ростова
Россия
г. Ростов


Г. Л. Игнатова
Кафедра терапии, фтизиопульмонологии и профпатологии УГМАДО
Россия
Челябинск


И. В. Лещенко
Уральская государственная медицинская академия; Медицинское объединение "Новая больница"
Россия
Екатеринбург


А. Г. Чучалин
ФГУ НИИ пульмонологии ФМБА России
Россия
Екатеринбург


Список литературы

1. Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Publication Number 2701, April 2001: 1–100. Available on: www.goldcopd.com

2. Burge S., Wedzicha J.A. COPD exacerbations: definitions and classifications. Eur. Respir. J. 2003; 21 (suppl. 41): 46s–53s.

3. Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 151: 1418–1422.

4. Donaldson G.C., Seemungal T.A.R., Bhowmik A., Wedzi# cha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852.

5. Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest. Dis. 1997; 52: 43–47.

6. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108 (suppl. 3): 43s–52s.

7. Ewig S., Rodriguez#Roisin R., Torres A. Indications for and choice of antibiotics in COPD. In: Similowski T., Whitelaw W.A., Derenne J. P., eds. Clinical management of chronic obstructive pulmonary disease. New York: Marcel Dekker Inc; 2002. 427–449.

8. Fagon J.#Y., Chastre J., Trouillet J.#L. et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am. Rev. Respir. Dis. 1990; 142: 1004–1008.

9. Soler N., Torres A., Ewig S. et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease requiring mechanical ventilation. Am. J. Respir. Crit. Care Med. 1998; 157: 1498–1505.

10. Eller J., Ede A., Schaberg T., Niederman M.S. et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–1548.

11. Nouira S., Marghli S., Belghith M. et al. Once daily oral ofloxacin in in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trail. Lancet 2001; 358: 2020–2025.

12. Blasi F., Tarsia P., Aliberti S. et al. Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. Pulm. Pharmacol. Therap. 2006; 19: 11–19.

13. O'Donnell J.A., Gelone S.P. The newer fluoroquinolones. Infect. Dis. Clin. N. Am. 2004; 18: 691–716.

14. Greenberg R.N. Overview of patient compliance with medication dosing: a literature review. Clin. Ther. 1994; 6: 592–599.

15. Yoo B.K., Triller D.M., Yong C.#S., Lodise T.P. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections. Ann. Pharmacother. 2004; 38: 1226–1235.

16. Blondeau J.M., Tillotson G. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections. Internat. J. Antimicrob. Agents 2008; 31: 299–306.

17. Hoban D.J., Bouchillon S.K., Johnson J.L. et al. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Diagn. Microb. Infect. Dis. 2001; 40: 51–57.

18. File T.M., Schlemmer B., Garau J. et al. Efficacy and safety of gemifloxacin in the treatment of community acquired pneumonia: a randomized, double blind comparison with trovafloxacin. J. Antimicrob. Chemother. 2001; 48: 67–74.

19. Lode H., File T.M., Mandell L. et al. Oral gemifloxacin versus sequental therapy with intravenosus ceftriaxone / oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community acquired pneumoniae: a randomized, open label, multicenter study of clinical efficacy and tolerability. Clin. Therapeut 2002; 24: 1915–1936.

20. Leophonte P., File T.M., Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin / clavulanic acid thrice daily for 10 days for the treatment of community acquired pneumonia of suspected pneumococcal origin. Respir Med 2004; 98: 708–720.

21. Anthonisen N.R., Manfreda J., Warren C.P.W. et al. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.

22. Beam T.R. Jr., Gilbert D.N., Lunin C.M., European Working Party. European guidelines for the clinical evaluation of antiinfective drug products. Munich: European Society for Clinical Microbiology and Infectious Diseases; 1993.

23. Murray P.R., Washington J.A. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin. Proc. 1975; 50: 339–344.

24. Cabello H., Torres A., Celis R. et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur. Respir. J. 1997; 10: 1137–1144.

25. Miravitlles M., Espinosa C., Fernandez#Laso E. et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116: 40–46.

26. Siempos I.I., Dimopoulos G., Korbila I.P. et al. Macrolides, quinolones, and amoxicillin/clavulanate for chronic bronchitis: a metaanalysis. Eur. Respir. J. 2007; 29: 1127–1137.

27. Jacobs M.R., Felmingham D., Appelbaum P.C., Gruneberg R.N., and the Alexander Project Group. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 2003; 52: 229–246.

28. Rittenhouse S., McCloskey L., Broskey J. et al. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens. J. Antimicrob. Chemother. 2000; 45 (suppl. S1): 23–27.

29. McCloskey L., Moore T., Niconovich N. et al. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA. J. Antimicrob Chemother 2000; 45 (suppl. S1): 13–21.

30. Biedenbach D.J., Jones R.N. Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolonesprevalence results from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. 2003; 46: 55–61.

31. Zhanel G.G., Palatnick L., Nichol K.A. et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolatesresults of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 2003; 47: 1867–1874.

32. Karlowsky J.A., Draghi D.C., Thornsberry C. et al. Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US. Int. J. Antimicrob. Agents 2002; 20: 76–85.

33. Davidson R., Cavalcanti R., Brunton J.L. et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 2002; 346: 520–521.

34. Urban C., Rahman N., Zhao X.L. et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J. Infect. Dis. 2001; 184: 794–798.

35. Nazir J., Urban C., Mariano N. et al. Levofloxacin resistant Haemophilus influenzae in a long-term care facility. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, September 27–30, 2002. San Diego; 2002. 96. C2–647.

36. Anderson K.B., Tan J.S., File Jr. T.M. et al. Emergence of levofloxacin resistant pneumococci in immunocompromised adults after therapy for community acquired pneumonia. Clin. Infect. Dis. 2003; 37: 376–381.

37. Zhao X., Drlica K. Restricting the selection of antibiotic-resistant mutantsa general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 2001; 33 (suppl. 3): S147–S156.

38. Sethi S., Fogarty C., Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir. Med. 2004; 98: 697–707.

39. Blondeau J. A review of clinical trials with fluoroquinolones with an emphasis on new agents. Exp. Opin. Invest. Drugs 2000; 9: 383–413.

40. Koeth L.M., Jacobs M.R., Bajaksouzian S. et al. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999–2000. Int. J. Antimicrob. Agents 2002; 19: 33–37.

41. Jones R.N., Biedenbach D.J. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community acquired respiratory tract infectionsNorth American results from the SENTRY Antimicrobial Surveillance Program (19992001). Diagn. Microbiol. Infect. Dis. 2003; 45: 273–278.

42. Wilson R., Langan C., Ball P. et al., Gemifloxacin 207 Clinical Study Group. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone / oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir. Med. 2003; 97: 242–249.

43. Wilson R., Schentag J.J., Ball P., 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical out comes. Clin. Ther. 2002; 24: 639–652.

44. Ball P., Wilson R., Mandell L.A. et al. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double-blind comparison with trovafloxacin. J. Chemother. 2001; 13: 288–298.

45. File Jr. T.M., Sclemmer B., Garau J. et al. Gemifloxacin versus amoxicillin / in the treatment of acute exacerbations of chronic bronchitis. J. Chemother. 2000; 12: 314–325.

46. Niederman M.S., McCombs J.S., Unger A.N. et al. Treatment costs of acute exacerbations of chronic bronchitis. Clin. Ther. 1999; 21: 576–591.

47. Cupo M., Pypstra R., Young C. Safety of gemifloxacin in adult patients with respiratory and urinary tract infections. Seventh Conference of the Federation of Infection Societies, Manchester, U.K., 29 November 1 December 2000. Abstr. P28.


Для цитирования:


Авдеев С.Н., Баймаканова Г.Е., Гайдар Е.Н., Игнатова Г.Л., Лещенко И.В., Чучалин А.Г. Эффективность и безопасность гемифлоксацина при инфекционном обострении хронической обструктивной болезни легких: открытое проспективное мультицентровое исследование. Пульмонология. 2008;(6):39-47. https://doi.org/10.18093/0869-0189-2008-0-6-39-47

For citation:


Avdeev S.N., Baimakanova G.E., Gaidar E.N., Ignatova G.L., Leshchenko I.V., Chuchalin A.G. Efficacy and safety of gemifloxacin in the treatment of acute exacerbation of chronic obstructive pulmonary disease: open prospective multicentre study. PULMONOLOGIYA. 2008;(6):39-47. (In Russ.) https://doi.org/10.18093/0869-0189-2008-0-6-39-47

Просмотров: 38


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)